Cargando…

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) shed new light on triple‐negative breast cancer (TNBC), but only a minority of patients demonstrate response. Therefore, adaptive immune resistance (AIR) needs to be further defined to guide the development of ICI regimens. METHODS: Databases, includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xin‐Yu, Li, Bin, Wang, Ye, Jin, Juan, Yang, Yu, Huang, Lei‐Huan, Yang, Meng‐Di, Zhang, Jian, Wang, Bi‐Yun, Shao, Zhi‐Ming, Ni, Ting, Huang, Sheng‐Lin, Hu, Xi‐Chun, Tao, Zhong‐Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508140/ https://www.ncbi.nlm.nih.gov/pubmed/37434394 http://dx.doi.org/10.1002/cac2.12465

Ejemplares similares

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy
por: Zhu, Yan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
por: Crosby, Erika J., et al.
Publicado: (2018)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer
por: Hu, Shaojun, et al.
Publicado: (2021)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
por: Klinke, David J
Publicado: (2014)

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
por: Xu, Chao, et al.
Publicado: (2023)

Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2022)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update()
por: Brown, Lauren C., et al.
Publicado: (2021)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer
por: Huang, Yun, et al.
Publicado: (2021)

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer
por: Liu, Jingyi, et al.
Publicado: (2022)

Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment
por: Zhang, Jinguo, et al.
Publicado: (2023)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
por: Sun, Dantong, et al.
Publicado: (2020)

Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
por: Palakurthi, Bhavana, et al.
Publicado: (2023)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Ji, Qiao, et al.
Publicado: (2021)

Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors
por: Hori, Junko, et al.
Publicado: (2020)

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC
por: Wang, Qian, et al.
Publicado: (2023)

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
por: Asano, Yuka, et al.
Publicado: (2018)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges
por: Uchimiak, Katarzyna, et al.
Publicado: (2022)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)

Dysregulated adaptive immune response contributes to severe COVID-19
por: Yu, Kuai, et al.
Publicado: (2020)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Correlation Between Immune Cell Infiltration and PD-L1 Expression and Immune-Related lncRNA Determination in Triple-Negative Breast Cancer
por: Yang, Wenlin, et al.
Publicado: (2022)

Development of an immune-related prognostic biomarker for triple-negative breast cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
por: Vito, Alyssa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7j6pcpt3ed3aguicu5naj2epbr